Skip to main content
About
Research and Development
CPI-613
®
(devimistat)
CB-839 (telaglenastat)
Leadership
Executive Management
Board of Directors
Contact Us
News & Investors
Press Releases
Clinical Trial Enrollment
Contact Us
Contact Us
Contact Us
Cornerstone Pharmaceuticals, Inc.
Email
:
info@cornerstonepharma.com
